106649-02-9

Usage

Uses

Used in Pharmaceutical Industry:
1-METHYL-1H-INDAZOLE-3-CARBOXY CHLORIDE is used as a precursor in the synthesis of various drugs, playing a crucial role in the development of new pharmaceuticals. Its ability to form more complex and biologically active molecules makes it a valuable component in drug discovery and medicinal chemistry.
Used in Agrochemical Industry:
1-METHYL-1H-INDAZOLE-3-CARBOXY CHLORIDE is also utilized as an intermediate in the synthesis of agrochemicals, contributing to the development of effective and innovative products for agricultural applications. Its role in creating complex molecules aids in the advancement of crop protection and pest management solutions.

Upstream product

• 50890-83-0 1-methyl-1H-indazole-3-carboxylic acid 
• 109216-60-6 1-Methyl-1H-indazole-3-carboxylic acid methyl ester 

Downstream Products

• 109889-09-0 granisetron 
• 128395-47-1 1-methyl-N-[(3-endo)-9-(phenylmethyl)-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide 
• 124998-65-8 granisetron 
• 107007-99-8 granisetron hydrochloride 
• 1404164-68-6 N-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1-methyl-1H-indazole-3-carboxamide 

Relevant academic research and scientific papers

A facile and simple synthesis of novel 2-(substituted)-5-(1-methyl-1H- indazol-3-yl)-oxazole derivatives

Novel 2-(substituted)-5-(1-methyl-1H-indazol-3-yl)-oxazoles (13) were synthesized in moderate yields, from 1-methyl-1H-Indazole 3-carboxylic acid (1), by converting it into a variety of amides (12) and further its heterocyclization. The structures of all the compounds have been elucidated on the basis of IR, 1H-NMR, and HRMS.

Catalytic syntheses of N-heterocyclic ynones and ynediones by in situ activation of carboxylic acids with oxalyl chloride

Breaking the bottleneck: α-Keto carboxylic acids and N-heterocyclic carboxylic acids are activated in situ with oxalyl chloride then catalytically alkynylated to give ynediones and N-heterocyclic ynones efficiently in a one-pot fashion. 5-Acylpyrazoles and 2-phenylaminopyrimidines, potentially interesting for pharmaceutical applications, are readily synthesized in concise one-pot, three-component syntheses. Copyright

Efficient syntheses of exo-granisetron hydrochloride and other potential impurities present in granisetron hydrochloride, an anti-emetic drug

European Pharmacopeia mentions about nine potential impurities in Granisetron hydrochloride. These impurities need to be controlled in the API as described in the Pharmacopeia. Elegant syntheses of four potential impurities in Granisetron hydrochloride are disclosed.

PROCESS FOR HIGHLY PURE CRYSTALLINE GRANISETRON BASE

The present invention discloses an improved, commercial process for the preparation of high purity (>99.9%) crystalline base of granisetron (1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide), having the formula (1), and its use in the process for the manufacture of pharmaceutically acceptable hydrochloride salt.

Process for preparing 1-methylindazole-3-carboxylic acid

A method of performing a bearer path assurance test across a packet-based IP network is provided. The method includes establishing a bearer path across the IP network and performing a bearer path assurance test during call setup before cutting through the call. The method can also include creating a timestamp at the originating office, sending the timestamp from the originating office to a terminating office, sending the timestamp from the terminating office to the originating office, receiving the timestamp at the originating office, and verifying the continuity of the bearer path. The method can also include evaluating round trip delay and packet loss using one or more timestamps.

Indazole derivatives having monocyclic amine

An indazole compound having the formula (I): wherein: R1 is hydrogen, C1 -C6 alkyl, C3 -C6 alkenyl or C3 -C6 cycloalkyl; Q is carbonyl, thiocarbonyl or methylene; and R2 is a group of the formula (II) or (IV); STR1 wherein R1 is C1 -C6 alkyl, C3 -C6 alkenyl or benzyl, of which a phenyl group thereof is optionally mono- or di-substituted by the same or different halogen or methoxy; m is 0 to 2; n and o is 1 or 2. The compound exhibits 5-HT4 receptor agonist activity.

DERIVATIVES OF AMIDE ANALOGS OF CERTAIN METHANO BRIDGED QUINOLIZINES

This invention relates to novel amide derivatives of certain 2, 6-methano-2H-quinolizine-type compounds, to the intermediates and processes for their preparation, to their ability to antagonize the effects of serotonin at the 5HT 3 receptors, and to their end-use application in the treatment of chemotherapeutically-induced nausea and vomiting, as anti-anxiety agents, in the symptomatic treatment of pain associated with migraine, as anti-arrhythmic agents, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses of the type manifested in patients suffering from schizophrenia, and mania, in the treatment of glaucoma, for stimulating gastric motility, to combat drug abuse, to treat sleep apnea and to treat irritable bowel syndrome.

Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof

The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of a medicament for the treatment of anxiety, psychosis, glaucoma and for the stimulation of gastric motility.

5-Hydroxytryptamine (5-HT3) Receptor Antagonists. 1. Indazole and Indolizine-3-carboxylic Acid Derivatives

Metoclopramide (1) is a gastric motility stimulant and a weak dopamine and 5-HT3 receptor antagonist.Conformational restriction of the (diethylamino)ethyl side chain of 1 in the form of the azabicyclic tropane gave 3, a very potent gastric motility stimulant and 5-HT3 receptor antagonist but devoid of significant dopamine receptor antagonist properties.Subsequent alteration of the aromatic nucleus led to the identification of indazoles 6a-h, and 1- and 3-indolizines 7b-d, and 8, and imidazopyridines 9 and 10, as potent 5-HT3 receptor antagonists devoid ofeither dopamine antagonist or gastric motility stimulatory properties.Further conformational restriction of the side chain identified quinuclidine 11 and isoquinuclidine 12 as potent 5-HT3 receptor antagonists which mimic the distorted chair conformation of the tropane with, in the case of 11, the N-methyl group axial.From these series, 6g (BRL 43694) was found to be both potent and selective and has been shown to be a very effective antiemetic agent against cytotoxic drug induced emesis both in the ferret and in man.

Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds

The present invention is directed to a group of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(3H)-ones and related compounds. The compounds are prepared from the appropriate carboxylic acids and alcohols by standard procedures or, where steric factors are significant, a new process which makes use of heavy metal salts of super acids can be used. The compounds involved are useful in the treatment of migraine and similar disorders and in cytotoxic drug-induced vomiting.